Weighing Benefits and Risks of CDK4/6 Inhibitors in HR+, HER2-Negative BC
It has been 5 years since the first cyclin-dependent kinase (CKD) 4/6 inhibitor was approved by the FDA for the management of advanced breast cancer (BC). The beneficial effects of these agents in improving overall survival in metastatic BC, however, remains unclear, and a systematic review sought to shed light on this subject. Read more.

NSAIDs and the Risk of Breast Cancer
It is postulated that the inhibition of COX-1 and COX-2 enzymes by nonsteroidal anti-inflammatory drugs (NSAIDs) may play a chemoprophylactic role against oncological diseases by promoting apoptosis and inhibiting mutagenesis. However, the data on the effects of this drug class in breast cancer prevention have been mixed. Read more.

Monitoring Breast Cancer Misinformation on Social Media
Health misinformation is widespread on the Internet, and this can have a devastating effect. Perhaps there is no disease state in which scientifically valid information is more necessary than in the management of cancer as timely, accurate information can save lives. Yet, the extent of misinformation on the Internet involving cancer remains undetermined. Read more.